Clinical Trial Update: A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update for STP938 in adults with relapsed or refractory B-cell and T-cell lymphomas is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• T-cell Lymphoma

Drugs mentioned

• STP938

Snippet

Sponsor: Step Pharma, SAS | Conditions: Lymphoma, B-Cell, Lymphoma, T-Cell | Phase 1, Phase 2 | Status: RECRUITING